Onglyza News and Research

RSS
Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Health Canada approves ONGLYZA for type 2 diabetes treatment

Health Canada approves ONGLYZA for type 2 diabetes treatment

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

FDA approves Onglyza (saxagliptin) for type 2 diabetes

FDA approves Onglyza (saxagliptin) for type 2 diabetes